Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

Last updated: March 14, 2025
Sponsor: Novo Nordisk A/S
Overall Status: Completed

Phase

3

Condition

Diabetes Prevention

Obesity

Treatment

Placebo (semaglutide 2.4 mg)

Semaglutide 2.4 mg

Clinical Study ID

NCT04998136
NN9536-4707
U1111-1265-5285
  • Ages > 18
  • All Genders

Study Summary

This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get placebo. Placebo is a "dummy" medicine that looks like the study medicine, but has no effect on the body.

Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm.

Participants will also have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight.

The study will last for about a year (50 weeks). Participants will have 10 clinic visits and 8 phone calls. At 6 of the clinic visits participants will have blood samples taken.

Participants cannot take part if participants have or have had diabetes. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age above or equal to 18 years at the time of signing informed consent.

  • BMI at least 25.0 kg/m^2 at screening.

  • Both parents of Asian descent.

  • History of at least one self-reported unsuccessful dietary effort to lose bodyweight.

Exclusion

Exclusion Criteria:

  • HbA1c at least 48 mmol/mol (6.5%) as measured by the central laboratory atscreening.

  • History of type 1 or type 2 diabetes mellitus.

  • A self-reported change in body weight above 5 kg (11 lbs) within 90 days beforescreening irrespective of medical records.

  • Any participant where a substantial weight loss, in the investigator's opinion,might jeopardise the participant's safety.

  • Renal impairment with estimated Glomerular Filtration Rate (eGFR) below 15mL/min/1.73 m^2 at screening.

Study Design

Total Participants: 150
Treatment Group(s): 2
Primary Treatment: Placebo (semaglutide 2.4 mg)
Phase: 3
Study Start date:
August 15, 2022
Estimated Completion Date:
November 20, 2023

Connect with a study center

  • Konyang university hospital

    Daejeon, 35365
    Korea, Republic of

    Site Not Available

  • Novo Nordisk Investigational Site

    Daejeon, 35365
    Korea, Republic of

    Site Not Available

  • Hallym University Sacred Heart Hospital

    Gyeonggi-Do, 14068
    Korea, Republic of

    Site Not Available

  • Novo Nordisk Investigational Site

    Gyeonggi-Do, 14068
    Korea, Republic of

    Site Not Available

  • Dongguk University Ilsan Hospital

    Gyeonggi-do, 10326
    Korea, Republic of

    Site Not Available

  • Novo Nordisk Investigational Site

    Gyeonggi-do, 10326
    Korea, Republic of

    Site Not Available

  • Gachon University Gil Hospital

    Incheon, 405-760
    Korea, Republic of

    Site Not Available

  • Novo Nordisk Investigational Site

    Incheon, 405-760
    Korea, Republic of

    Site Not Available

  • Novo Nordisk Investigational Site

    Seongnam-si, Gyeonggi-do, 13620
    Korea, Republic of

    Site Not Available

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620
    Korea, Republic of

    Site Not Available

  • Novo Nordisk Investigational Site

    Seoul, 07061
    Korea, Republic of

    Site Not Available

  • SMG-SNU Boramae Medical Center

    Seoul, 07061
    Korea, Republic of

    Site Not Available

  • Ajou University Hospital

    Suwon, 16499
    Korea, Republic of

    Site Not Available

  • Novo Nordisk Investigational Site

    Suwon, 16499
    Korea, Republic of

    Site Not Available

  • Division of Nutrition and Biochemical Medicine

    Bangkok, 10400
    Thailand

    Site Not Available

  • King Chulalongkorn Memorial Hospital_Bangkok

    Bangkok, 10330
    Thailand

    Site Not Available

  • Novo Nordisk Investigational Site

    Bangkok, 10400
    Thailand

    Site Not Available

  • Obstetrics&Gynecology King Chulalongkorn Memorial Hospital

    Bangkok, 10330
    Thailand

    Site Not Available

  • Siriraj Hospital_Bangkok_1

    Bangkok, 10700
    Thailand

    Site Not Available

  • Siriraj Institute of Clinical Research

    Bangkok, 10700
    Thailand

    Site Not Available

  • Maharaj Nakorn Chiang Mai Hospital

    Chiang Mai, 50200
    Thailand

    Site Not Available

  • Novo Nordisk Investigational Site

    Chiang Mai, 50200
    Thailand

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.